Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE

Inclusion Criteria: * Age older than 50 years * Fulfilled the Chuang criteria * And currently: * PMR-AS\> 10 * Absence of signs or symptoms of other musculoskeletal or connective tissue conditions * Able to give informed consent * Concomitant treatments with methotrexate or hydroxy-chloroquine are permitted if stable dose since 3 months. Exclusion Criteria: * Clinical symptoms of giant cell arteritis * Uncontrolled dyslipidemia, high blood pressure or cardiovascular disease * History of major organ or haematopoietic stem cell/marrow transplant * Clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to PMR * Planned surgical procedure within 12 months after randomization. * History of malignant neoplasm within the last 5 years. * Current active infection * Patient with elevated ALT or AST\> 5 ULN